Overview

A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy

Status:
Completed

Trial end date:
2015-06-03

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and efficacy of the combination of rituximab and methotrexate to treat disabling fibrosing skin disorders.Rituximab will be administered at baseline and month 6. The drug will be considered efficacious if the skin thickness diminishes substantially.

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital, Ghent

Treatments:

Rituximab